Jamie Dananberg Biography and Net Worth

Insider of Annexon

Dr. Dananberg joined Annexon as Chief Medical Officer in July 2023. He previously served as Chief Medical Officer at UNITY Biotechnology, where as one of its earliest employees, he built the medical and broader development organization. Prior to UNITY, he served in several roles across multiple indications as Executive Vice President at Takeda Pharmaceuticals, and before that, he spent 16 years at Eli Lilly & Co. bringing more than 100 programs from discovery to development, leading and supporting efforts through all phases, including the launches of multiple commercial products. Dr. Dananberg started his career practicing medicine in endocrinology and metabolism and ran a basic science laboratory at the University of Michigan. He received his B.S. and M.D. degrees from Tufts University.

What is Jamie Dananberg's net worth?: The estimated net worth of Jamie Dananberg is at least $150.32 thousand as of February 18th, 2025. Dananberg owns 33,479 shares of Annexon stock worth more than $150,321 as of December 5th. This net worth estimate does not reflect any other assets that Dananberg may own. Learn More about Jamie Dananberg's net worth.
How old is Jamie Dananberg?: Dananberg is currently 66 years old. There are 4 older executives and no younger executives at Annexon. Learn More on Jamie Dananberg's age.
How do I contact Jamie Dananberg?: The corporate mailing address for Dananberg and other Annexon executives is , , . Annexon can also be reached via phone at 650-822-5500 and via email at [email protected]. Learn More on Jamie Dananberg's contact information.
Has Jamie Dananberg been buying or selling shares of Annexon?: Jamie Dananberg has not been actively trading shares of Annexon in the last ninety days. Most recently, Jamie Dananberg sold 5,521 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $2.96, for a transaction totalling $16,342.16. Following the completion of the sale, the insider now directly owns 33,479 shares of the company's stock, valued at $99,097.84. Learn More on Jamie Dananberg's trading history.
Who are Annexon's active insiders?: Annexon's insider roster includes Dean Artis (EVP), William Carson (Director), Jamie Dananberg (Insider), Sanjay Keswani (EVP), Jennifer Lew (CFO), Douglas Love (CEO), Michael Overdorf (EVP), Muneer Satter (Director), and Ted Yednock (EVP). Learn More on Annexon's active insiders.
Are insiders buying or selling shares of Annexon?: During the last twelve months, Annexon insiders bought shares 10 times. They purchased a total of 1,876,188 shares worth more than $7,268,165.34. During the last twelve months, insiders at the sold shares 12 times. They sold a total of 32,352 shares worth more than $93,274.67. The most recent insider tranaction occured on December, 1st when Director Jung Choi bought 33,000 shares worth more than $138,270.00. Insiders at Annexon own 11.9% of the company. Learn More about insider trades at Annexon.
Information on this page was last updated on 12/1/2025.

Jamie Dananberg Insider Trading History at Annexon

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/18/2025	Sell	5,521	$2.96	$16,342.16	33,479

Jamie Dananberg Buying and Selling Activity at Annexon

Annexon Company Overview

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Today's Range

Now: $4.49

$4.25

$4.55

50 Day Range

MA: $3.38

$2.68

$4.51

2 Week Range

Now: $4.49

$1.28

$5.66

Volume

2,488,278 shs

Average Volume

3,148,846 shs

Market Capitalization

$537.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2

Jamie Dananberg Biography and Net Worth

What is Jamie Dananberg's net worth?

How old is Jamie Dananberg?

How do I contact Jamie Dananberg?

Has Jamie Dananberg been buying or selling shares of Annexon?

Who are Annexon's active insiders?

Are insiders buying or selling shares of Annexon?